MEDICAMEQ · Medicamen Biotech Limited · Financials
Volume · Nov 13
1340
Avg daily vol (3M)
3775
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Income-statement, balance-sheet and cash-flow figures read from the company's own published financial reports.
Revenue
1.98B
+21.7%
FY2026
Net Income
96.41M
+35.6%
FY2026
Operating Cash Flow
-331.72M
-361.1%
FY2026
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|---|---|
| INR | 2.03B | 1.98B | 1.63B | 1.79B | 1.41B | 1.15B |
| INR | 72.04M | 72.19M | 70.66M | 70.93M | 63.67M | 57.71M |
| INR | 31.73M | 34.97M | 31.56M | 43.97M | 29.23M | 14.01M |
| INR | 124.25M | 119.85M | 98.8M | 130.76M | 170.45M | 180.94M |
| INR | 23.83M | 21.88M | 33.24M | 35.82M | 23.17M | 31.97M |
| INR | 108.3M | 96.41M | 71.08M | 109.31M | 148.44M | 0 |
Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.
Capital Returned to Shareholders
Cash spent on share repurchases and dividends per fiscal year, as reported on the cash-flow statement. Across FY2022–FY2026: 63.8M in dividends.
Debt Profile
No verified debt profile is available yet. This does not establish that the company has no debt or covenants.